Adenoviral expression of murine serum amyloid A proteins to study amyloid fibrillogenesis.
Serum amyloid A (SAA) proteins are one of the most inducible acute-phase reactants and are precursors of secondary amyloidosis. In the mouse, SAA1 and SAA2 are induced in approximately equal quantities in response to amyloid induction models. These two isotypes differ in only 9 of 103 amino acid residues; however, only SAA2 is selectively deposited into amyloid fibrils. SAA expression in the CE/J mouse species is an exception in that gene duplication did not occur and the CE/J variant is a hybrid molecule sharing features of SAA1 and SAA2. However, even though it is more closely related to SAA2 it is not deposited as amyloid fibrils. We have developed an adenoviral vector system to overexpress SAA proteins in cell culture to determine the ability of these proteins to form amyloid fibrils, and to study the structural features in relation to amyloid formation. Both the SAA2 and CE/J SAA proteins were synthesized in large quantities and purified to homogeneity. Electron microscopic analysis of the SAA proteins revealed that the SAA2 protein was capable of forming amyloid fibrils, whereas the CE/J SAA was incapable. Radiolabelled SAAs were associated with normal or acute-phase high-density lipoproteins (HDLs); we examined them for their clearance from the circulation. In normal mice, SAA2 had a half-life of 70 min and CE/J SAA had a half-life of 120 min; however, in amyloid mice 50% of the SAA2 cleared in 55 min, compared with 135 min for the CE/J protein. When the SAA proteins were associated with acute-phase HDLs, SAA2 clearance was decreased to 60 min in normal mice compared with 30 min in amyloidogenic mice. Both normal and acute-phase HDLs were capable of depositing SAA2 into preformed amyloid fibrils, whereas the CE/J protein did not become associated with amyloid fibrils. This established approach opens the doors for large-scale SAA production and for the examination of specific amino acids involved in the fibrillogenic capability of the SAA2 molecule in vitro and in vivo.
Kindy
M S
MS
Department of Biochemistry, University of Kentucky School of Medicine, 800 Rose Street, Lexington, KY 40536-0084, USA. mskindy@pop.uky.edu
King
A R
AR
Yu
J
J
Gerardot
C
C
Whitley
J
J
de Beer
F C
FC
D000209:Acute-Phase Proteins / Q000378:metabolism; D000256:Adenoviridae / Q000235:genetics*; D017772:Amyloid Neuropathies / Q000097:blood; D000818:Animals; D002460:Cell Line; D002461:Cell Line, Transformed; D005822:Genetic Vectors; D000882:Haplorhini; D008075:Lipoproteins, HDL / Q000097:blood / Q000737:chemistry; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008854:Microscopy, Electron; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000097:blood / Q000235:genetics / Q000648:ultrastructure; D000685:Serum Amyloid A Protein / Q000096:biosynthesis* / Q000235:genetics / Q000648:ultrastructure
D000209:Acute-Phase Proteins; D008075:Lipoproteins, HDL; D011994:Recombinant Proteins; D000685:Serum Amyloid A Protein